Connor, Clark & Lunn Investment Management Ltd. Caribou Biosciences, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$4.04 - $5.47 $335,606 - $454,398	83,071 Added 104.95%	162,221 $689,000
Q1 2023 May 09, 2023	BUY	$4.3 - $7.78 $149,592 - $270,658	34,789 Added 78.42%	79,150 $420,000
Q4 2022 Feb 10, 2023	BUY	$5.57 - $11.01 $247,090 - $488,414	44,361 New	44,361 $278,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

Black Rock Inc. New York, NY

6.95M
Shares

$13 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.62M
Shares

$8.64 Million
0.0% of portfolio
Bank Of America Corp Charlotte, NC

4.57M
Shares

$8.55 Million
0.0% of portfolio
Pfm Health Sciences, LP San Francisco, CA

4.31M
Shares

$8.05 Million
0.49% of portfolio
Kynam Capital Management, LP Princeton, NJ

2.36M
Shares

$4.41 Million
0.38% of portfolio

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $114M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account